RE:$6.50 down to $1.50I definitely miss the Dawson Reimer days--stock was flying high back then. He might have had a hand in the short partnership with Knight Therapeutics which ultimately led to the Apicore purchase & eventual sale that landed the sizeable cash pile. Fast-forward under Friessens tenure and we're almost back to square one. Cash is nearly depleted, aggrastat sales are in decline--and serious mis-use of company cash to the point where a share offering is a possibility. This company needs a new perspective to lead.